Objectives: The success of highly active antiretroviral therapy (HAART) in HIV infection may be influenced by numerous host factors. There is a lack of data presenting a combined assessment of a variety of these parameters for treatment efficacy in clinical routine practice.
Introduction
Highly active antiretroviral therapy (HAART) for HIV infection has led to reduced morbidity and mortality in treated individuals. 1 However, in a substantial proportion of patients the effectiveness of HAART is not sufficient with the consequence of virological failure and immunological decay. 2 One element that has been identified as essential for a successful HAART combination is therapeutic drug monitoring (TDM), which is valuable for the management of insufficient bioavailability of medication, the determination of drug interactions and the prevention of toxic effects. [3] [4] [5] [6] Plasma drug concentrations of antiretroviral compounds have been linked to virological outcome of HAART. [7] [8] [9] The application of TDM in daily practice remains controversial; 3 however, it has been described as cost-effective. 10 Furthermore, it has been demonstrated that adherence is independently associated with virological failure, clinical progression and mortality, [11] [12] [13] [14] [15] [16] [17] and insufficient protease inhibitor (PI) concentrations are linked to low adherence. 13, 18 A further field of research into the prediction of short-term success of HAART is health-related quality of life (HRQL). The beneficial impact of HAART on HRQL has been demonstrated; however, the influence of HRQL on treatment success remains in question. [19] [20] [21] Finally, there is evidence that social status has a moderate but significant impact on the outcome of HAART. [22] [23] [24] [25] Very few studies exist investigating the influence of these factors within a combined approach. 14, 26, 27 Moreover, it is unclear which tools provide the best information for patient management [i.e. pharmacokinetic (PK) parameters trough levels, unscheduled monitoring or complete PK assessments of TDM in clinical routine]. 4, 7, 14, 28, 29 The aim of the present study was to evaluate the effect of TDM in relation to clinical characteristics, adherence, indicators of quality of life and social status upon short-term success of HAART within a non-selected patient group.
Methods
The ADDMORE project is an ongoing prospective investigation evaluating ADherence, Drug MOnitoring and REsistance testing in HIV-infected patients treated with HAART. We studied an unselected cohort that underwent TDM while on stable HAART for more than 3 months. Patients were randomly enrolled in routine clinical practice in a university out-patient unit specialized for infectious diseases. The local institutional review board approved the protocol of the study.
Plasma concentrations of all commercially available PI and nonnucleoside reverse transcriptase inhibitors (NNRTI) were measured. PK samples were taken at enrolment after informed consent was obtained. Simultaneously, patients completed a questionnaire to assess drug adherence, socioeconomic indices and HRQL. During a second visit 4 weeks later, patients underwent a scheduled PK assessment to measure trough level and hourly plasma concentrations up to 4 h after standardized drug ingestion with breakfast with the exception of efavirenz. PK analysis of efavirenz was performed at the same time-points as for the other compounds; however, the drug was taken the night before measurement at the time of regular administration. In patients demonstrating a viral load above 50 copies/mL under therapy, the scheduled visit was performed 4 weeks after treatment switch. Concentrations were determined by validated HPLC, as described previously. 30 Concentration thresholds for trough levels (C trough ) as well as the lower value of the therapeutic range were defined as shown in Table 1 . The value for ritonavir, applied as a booster (/r), was not used for the analysis. To create a comparable classification of the values of PK assessments, the determined drug levels were defined as sufficient or insufficient. Concentrations at unscheduled visits and trough levels were regarded as sufficient if values exceeded the mentioned C trough . The 4 h pharmacokinetic profile (PK-profile) was regarded as sufficient if all values were above the C trough and at least one level of each measured compound exceeded the lower value of the therapeutic range.
Demographic and clinical characteristics, CD4 cell count and viral load at baseline were recorded. The questionnaire consisted of items that covered the areas of adherence, HRQL and social determinants. Adherence was assessed considering self-efficacy, evaluating the belief of the patients to be able to be compliant with the prescribed combination scheme (yes, no), and correctness of medication intake, assessed by the question of having forgotten a drug dose within the last 2 days, 14 days, last weekend or never. Adherence data were transformed to dichotomous variables for further analysis, dividing the results into complete and less than complete adherence. HRQL was measured using validated methods as described before. 31, 32 We selected the questions originally published as numbers 2, 3, 5, 7-18 in the Medical Outcomes Study. 32 Answers were grouped to combined indicators as validated before, resulting in the variables general, mental and HIV-associated HRQL. 32 The 'general' variable consisted of item 1 from the Medical Outcomes Study 32 plus the following question: 'To what extent is your well-being reduced by your HIV infection? (very much, much, moderate, not reduced)'. The 'HIV-associated' variable consisted of the question as described before plus items 13e-h from the Medical Outcomes Study. 32 The 'mental' variable was defined according to the Medical Outcomes Study. 32 School education and professional qualification (each as completed graduation) were used as social indicators. The analysis of ordinal variables was performed after transformation to a scale ranging from 0 to 100, with 0 representing the lower edge of the scale. Follow-up consisted of viral load measurements at weeks 12 and 24. In addition, we monitored all modifications of HAART dosage, including those increases due to insufficient drug levels as well as discontinuations due to drug toxicity or virological failure.
The statistical analysis was performed with SPSS, release 12.1. Univariate comparisons were applied using the t-test or two-sided Fisher's exact test, where appropriate. Multivariate analyses were performed with the help of logistic regression models. P values < 0.05 were considered significant; no adjustment for multiple testing was done.
Results
Altogether, 210 patients participated in the study between 2002 and 2004. The baseline characteristics of this population are described in Table 2 . Patients were treated with the following quantifiable antiretroviral drugs, used as a single or boosted agent: ritonavir-boosted amprenavir (n = 10), ritonavir-boosted atazanavir (n = 30), efavirenz (n = 24), ritonavir-boosted lopinavir (n = 78), nelfinavir (n = 17), nevirapine (n = 23), ritonavirboosted saquinavir (n = 4). The following combinations of compounds were applied: efavirenz and ritonavir-boosted lopinavir (n = 4), nevirapine and ritonavir-boosted amprenavir (n = 2), nevirapine and ritonavir-boosted lopinavir (n = 8), ritonavir-boosted lopinavir and amprenavir (n = 3), ritonavirboosted lopinavir and saquinavir (n = 7), ritonavir-boosted saquinavir and atazanavir (n = 1). At unscheduled PK measurement, 87.3% of individuals had sufficient drug levels, 12.7% showed low concentrations. C trough on the day of appointment for PK was above the lower cut-off in 82.9% of cases and below this level in 17.1% (n = 36). Of these, 17 had a detectable viral load at baseline, and 19 had a viral load below the detection limit, respectively. The 4 h PK-profile showed sufficient concentrations in 61.9%, whereas in 38.1% the concentration was regarded as insufficient. In 16.7% of patients, a dose adjustment due to low concentrations was applied. Considering adherence, 97.0% of individuals pledged to take the prescribed medication regularly; 3.0% declined to pledge or gave no answer. In 88.4% medication intake was considered to be complete; 11.6% of the patients admitted missing a dose or gave no answer. HRQL results, after conversion to a metric scale, were as follows: mean value of the combined variables (-SD) of general HRQL was 65.4 (-21), for mental HRQL it was 66.3 (-21) and for HIV-associated HRQL it was 69.7 (-22) . The social determinant of school education showed intermediate or high graduation levels in 40.7% and low or no qualification in 59.3%. Considering professional education, 17.0% of cases had intermediate or high graduation levels and 83.0% had a low or no qualification.
All but two patients were monitored for 24 weeks. No discontinuations of HAART occurred, but 11 patients switched antiretroviral therapy due to side effects or insufficient decline of viral load within the follow-up period. Univariate analysis identified the following parameters as being significantly associated with suppression of viral replication at 12 weeks: baseline viral load, unscheduled drug levels, the 4 h PK-profile and completeness of drug intake (see Table 3 ). At 24 weeks, only baseline viral load, the PK-profile and correctness of medication intake were significantly associated with suppression of viral replication. There was a tendency towards an association of the trough level of the PK-profile with virological efficacy at 12 weeks that did not reach statistical significance. The assessed variables of HRQL, social status and the question on self-efficacy were not predictive for virological success.
In the multivariate analyses, three different models of combinations of confounding variables were tested, which correspond to the items that were found to be significantly associated with virological efficacy in univariate analysis (baseline patient characteristics, the different PK assessments and the adherence question on correctness of drug intake) ( Tables 4 and 5 ). Additionally, the parameters baseline CD4 cell count, body mass index and dosage modification due to low drug levels were included, as these were considered to be of significant impact on treatment outcome. Baseline viral load and each of the PK tests were significantly associated with virological success of therapy at 12 weeks, but not at 24 weeks. Adherence measured by correctness of drug intake was significantly associated with effective HAART at 12 and 24 weeks.
No association was found between the PK tests and adherence indicators or between baseline viral load and PK sampling or adherence. Furthermore, parameters found not to be significantly associated with treatment outcome in univariate analysis were also found not to be associated in two different models of multivariate analysis (data not shown).
In summary, baseline viral load, PK variables and adherence measured by completeness of drug intake in the near past were significantly associated with virological efficacy at 12 weeks. With the exception of C trough (non-significant in univariate analysis), this result was valid both in univariate and multivariate analyses. At 24 weeks, the 4 h PK-profile (in univariate analysis) and the adherence question on medication intake (in both analyses) were associated with success. The other tested variables did not show a significant association with virological outcome.
Discussion
Combined analyses of factors influencing the outcome of HAART are scarce. Aside from trials on specific regimens, several studies have addressed aspects such as baseline clinical characteristics, TDM and adherence as predictors of therapeutic success (see discussion in Reference 14) . However, only a minority of investigations used a combined analysis for detecting independent factors. 8, 33 Thus, the purpose of our study was to assess the significance of a variety of clinical characteristics and different means of HAART monitoring on virological success of treatment. This was a prospective study, which tested parameters that have previously been shown to have an impact on HAART efficacy. Individuals were enrolled in daily practice in a nonselected manner. Altogether, 210 individuals were studied, predominantly middle-aged normal-weight Caucasian males with homosexual HIV transmission. Applied regimens consisted of modern combinations including NNRTI or boosted PI. The cohort was moderately advanced in the course of HIV disease, more than half of the cases were treated sufficiently with HAART. All determined parameters were classified in a manner that allowed a normalized comparison. We found sufficient drug levels and good adherence indices in the vast majority of the patients, matching the results of several previous investigations. 34 Mean quality of life indices ranked as good for this population. The majority of cases belonged to groups with lower social determinants.
We identified baseline viral load, unscheduled drug level, a 4 h PK-profile and the question on correctness of medication intake in the near past as the most important predictors of virological success. Clinical status, CD4 cell count, indicators of social status and HRQL were not associated with virological outcome. Baseline viral load is well-known to be of significant impact on clinical and virological progression, 35 and, not surprisingly, our data are in concordance with this fact. The more important finding is the significant association of different strategies of PK sampling and adherence estimation with suppression of viral replication at 12 weeks, and, to a lesser extent, at 24 weeks. This association is independent of the other assessed parameters that did not influence HAART efficacy in the described context. Thus, our data provide an insight into the strength of association of different clinical aspects with short-term virological outcome. The results are comparable to those from a study that assessed similar factors in a HAART-naive population treated with indinavir. 14 For the clinician, the parameters unscheduled PK analysis and the scheduled 4 h PK-profile as well as the adherence estimation by correctness of drug intake were valuable predictors of success. The other means of monitoring were inferior in predicting outcome. Thus, we present simple diagnostic tools that may improve HAART efficacy by identification of patients with a risk of short-term failure. Finally, HRQL and social determinants had no detectable influence on outcome.
In conclusion, we identified easy-to-assess variables with significant impact on HAART efficacy in a prospective cohort representing routine clinical practice. Furthermore, we were able to identify parameters with little effect on treatment results. This may help to improve management of patients treated with HAART. The debate about practical tools for assessing drug levels is not finished. 4, 7, 36 We showed that TDM is capable of predicting virological outcome, a fact that has previously been demonstrated. 8, 9, 37 The new aspect highlighted by our results is the independent association of PK sampling with efficacy after adjustment for a number of important confounders such as baseline virological and immunological values, adherence, HRQL and social indices. This is valid especially for the 4 h PK-profile, which produced the clearest association with virological success. The information gained by a PK-profile may thus provide the best estimation of future efficacy of HAART. However, this measurement is only achievable with substantial effort by both the clinician as well as the patient, who has to present to the treatment centre at appointment fasting and must remain for the whole morning. Thus, the PK-profile may not be the most feasible tool to measure bioavailability of drugs in daily practice.
It is notable that an unscheduled drug level was almost as clearly associated with virological outcome as the complete 4 h profile in a scheduled PK assessment. Other retrospective trials showed similar results without consideration of different confounders. 26, 28, 38 Untimed drug levels were sensitive identifiers of individuals who had been adherent to 60% or less of medication doses in a cross-sectional study. 29 In another study, a low drug level on random testing was significantly associated with poor clinical response to therapy. 28 Moreover, in our study untimed drug levels were more valuable in predicting outcome than trough levels at scheduled appointments. As the unscheduled measurement is an easily applicable and cheap method, it may be of considerable value in detecting patients with a high risk of short-term virological failure. Reasons for this association may include reduced adherence, poor absorption of drugs or individual metabolic disposition. PK results were not associated with adherence in our dataset, a finding previously described for indinavir-based therapy. 39 In another study, unscheduled drug levels were associated only with very low adherence. 29 Further trials demonstrated a moderate association of PI levels and adherence. 18, 40, 41 Thus, a complete understanding of the connection of these parameters remains elusive. As we could not find a substantial association of adherence with PK levels or PK data with baseline viral load, the assessed parameters are more likely to serve as risk factors for future treatment failure than they are able to explain treatment efficacy at a certain time point. The question about correctness of medication intake in the last 14 days turned out to be of substantial benefit for treatment efficacy at 12 and 24 weeks. This is in line with published data. 11, 15, 16, 33, 42 Adherence measured by self-administered questionnaires has been shown to correlate with methods such as direct and indirect pill count 12 and was an independent risk factor for viral rebound in other studies. 35, 43 Owing to a broader evaluation of confounding variables, we were able to show that adherence plays a more important role for short-term treatment outcome than do the above mentioned parameters. Moreover, self-reported accuracy of drug intake was a better predictor of success than the personal estimation of future adherence.
Several biases of our results must be considered. First, the studied patient group is diverse in respect to the large number of different HAART combinations. Thus, the information on specific characteristics of each combination used in antiretroviral therapy and especially class-specific effects was lost due to this population approach. As such, the results of this investigation cannot be compared with other trials that studied only single defined combinations of drugs. However, our study was designed to represent contemporary clinical reality. Consequently, while the administered regimens show a large variety of combinations and the conclusions of the whole study may not be valid for each individual combination, the facts may be regarded as representative of antiretroviral therapy in daily practice. Second, a substantial subgroup had non-suppressive HAART at baseline. This mixture of cases is unique in our dataset and again underscores the validity of the results for clinical routine, where HAART combinations without suppressed viral replication are common. Third, our study aimed at modelling easy-to-apply parameters as tools for the clinician. To this end we used a normalized classification scheme for interindividual comparisons. By ignoring drug-specific effects in defined patient subgroups, we gained an estimation of the effects of different monitoring methods on a population basis. This led to the characterization of the value of different diagnostic applications rather than the analysis of singleagent-characteristics. Moreover, the administered regimens present a cross-sectional description of currently applied HAART concepts. Fourth, the lack of an association between PK results and baseline viral load shows that the applied parameters may only serve as risk factors for future development rather than monitoring tools for a current clinical situation. Accordingly, a number of individuals with insufficient drug levels at baseline show virological control at study endpoints. Thus, patients demonstrating unfavourable results should undergo intensive counselling in order to improve the likelihood of effective control of viral replication. Fifth, classification PK levels in the 4 h profile were quite generous, as a relatively low profile could still be regarded as sufficient. We attempted to define PK levels that would be applicable to daily practice. Sixth, our findings are valid only for short-term efficacy of antiretroviral therapy. More information over longer follow-up periods is necessary to gain a better understanding of the relevance of the studied parameters. Finally, by only recording increases in dosing, we did not take into account the important application of TDM to identify cases with toxic drug levels. While this parameter has been shown to be of significant value for improving administration of HAART, 6 we may have underestimated its effect in our investigation. The low number of treatment discontinuations or switches indicates, however, that this factor may have a low impact on the results. Taken together, the discussed limitations imply a need for cautious interpretation of the results, but do not outweigh the validity of the data within daily practice. Thus, our results are of value for clinical routine.
In conclusion, we identified unscheduled PK measurement and self-reported adherence as independently associated with shortterm virological success of HAART in routine clinical practice. By considering these aspects, the clinician is able to apply diagnostic tools of identifying individuals with a possible risk of treatment failure with reasonable effort and low expense. Interventions for better adherence and diagnostics for reasons of suboptimal bioavailability of drugs may follow. Besides baseline viral load, the variety of other studied factors could not be associated with effective HAART.
